NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Clinical Trials (5)
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
Started Jun 2012
10 enrolled
Hypercholesterolemia, FamilialHeterozygous Familial Hypercholesterolemia
Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease
Started Oct 2011
32 enrolled
Coronary Artery DiseaseDyslipidemias
Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
Started Sep 2011
244 enrolled
Dyslipidemia
Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
Started May 2011
1,139 enrolled
Primary HypercholesterolemiaMixed Dyslipidemia
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
Started Mar 2011
1,173 enrolled
Primary HypercholesterolemiaMixed Dyslipidemia